Abbott Gets Sub-license to Develop Companion Dx for Pfizer Drug

Pfizer will issue a sub-license to Abbott to develop diagnostic products to screen NSCLC tumors for the presence of rearrangements in the ALK gene.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.